Pathogenesis of bone erosions in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 12, Issue 3, 2000, Pages 195-199

  Goldring, Steven R ^a,b,c   Gravallese, Ellen M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE EROSION; HUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 0034009870     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200005000-00006     Document Type: Review

References (69)

1. 1 Goldring SR, Polisson RP: Bone disease in rheumatological disorders, In Metabolic Bone Disease, 2nd edn. Edited by Avioli L, Krane SM. San Diego: Academic Press; 1998:621-635.
2. 2 Deodhar AA, Woolf AD: Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996, 35:309-322.
3. 3 Gough AK, Lilley J, Eyre S, Holdin R, Emery P: Generalized bone loss in patients with rheumatoid arthritis. Lancet 1994, 344:23-27.
4. 4 Spector TD, Hall GM, McCloskey EV, Kanis JA: Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993, 306:558.
5. 5 Beat AM, Bloch DA, Fries JF: Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991, 18:804-808.
6. 6 Sambrook P, Nguyen T: Vertebral osteoporosis in rheumatoid arthritis. Br J Rheum 1992, 31:573-574.
7. 7 Als OS, Gotfredsen A, Riis BJ, Christiansen C: Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis? Ann Rheum Dis 1985, 44:406-411.
8. 8 Lane NE, Goldring SR: Bone loss in rheumatoid arthritis: what role does inflammation play? J Rheumatol 1998, 7:1251-1253.
9. 9 Sharp JT, Wolfe F, Mitchell DM, Bloch DA: The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991, 34:660-668.
10. 10 van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC: Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol 1993, 20:1288-1296.
11. 11 Parfitt AM: Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994, 55:273-286.
12. 12 Raisz LG: Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988, 318:818-828.
13. 13 Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305-311.
14. 14 Vaananen H: Osteoclast function: biology and mechanisms. In Principles of bone biology. Edited by Bilezikian JP, Raisz L, Rodan GA. London: Academic Press; 1996:103-113.
15. 15 Vaananen H, Horton M: The osteoclast clear zone is a specialized cell-extra-cellular matrix adhesion structure. J Cell Sci 1995, 108:2727-2732.
16. 16 Suda T, Nakamura I, Jimi E, Takahashi N: Regulation of osteoclast function. J Bone Miner Res 1997, 12:869-879.
17. 17 Tezuka K, Nemoto K, Tezuka Y, Sato T, Ikeda Y, Kobori M, Kawashima H, Eguchi H, Hakeda Y, Kumegawa M: Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J Biol Chem 1994, 269:15006-15009.
18. 18 Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T: Molecular cloning of human cDNA for cathepsin K: novel proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995, 206:89-96.
19. 19 Hattersley G, Chambers TJ: Generation of osteoclastic function in mouse bone marrow cultures: multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. Endocrinology 1989, 124:1689-1696.
20. 20 Suda T, Takahashi N, Martin TJ: Modulation of osteoclast differentiation. Endocr Rev 1992, 13:66-80.
21. 21 Takahashi N, Akatsu T, Sasaki T, Nicholson GC, Moseley JM, Martin TJ, Suda T: Induction of calcitonin receptors by 1 alpha, 25-dihydroxyvitamin D3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. Endocrinology 1988, 123:1504-1510.
22. 22 Hattersley G, Chambers TJ: Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology 1989, 125:1606-1612.
23. 23 Lee SK, Goldring SR, Lorenzo JA: Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. Endocrinology 1995, 136:4572-4581.
24. 24 Su Y, Chakraborty M, Nathanson M, Baron R: Differential effects of the 3′,5′-cyclic adenosine monophosphate and protein kinase C pathways on the response of isolated rat osteoclasts to calcitonin. Endocrinology 1992, 131:1497-1502.
25. 25 Chambers TJ, Hall TJ: Cellular and molecular mechanisms in the regulation and function of osteoclasts. Vit Horm 1991, 46:41-86.
26. 26 Leisen JCC, Duncan H, Riddle JM, Pitchford WC: The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. J Rheumatol 1988, 15:17-22.
27. 27 Bromley M, Woolley DE: Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984, 27:968-975.
28. 28 Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR: Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951.
29. 29 Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258
30. 30 Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin T, Suda T: Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-285.
31. 31 Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson D, Suda T: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors. J Exp Med 1999, 190:1741-1754.
32. 32 Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med 1996, 183:2581-2591.
33. 33 Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
34. 34 Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
35. 35 Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Min Res 2000, 15:2-12.
36. 36 Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998, 250:776-781.
37. 37 Horwood NJ, Elliott J, Martin TJ, Gillespie MT: Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998, 139:4743-4746.
38. 38 Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997, 186:2075-2080.
39. 39 Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, 3rd, Frankel WN, Lee SY, Choi Y: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
40. 40 Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
41. 41 Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
42. 42 Simonet WS, Lacey DL, Dunstan CR, Kelly M, Chang MS, Luthy R, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
43. 43 Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
44. 44 Feldmann M, Brennan F, Paleolog E, Taylor P, Maini RN: Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action. Eur Cytokine Network 1997, 8:297-300.
45. 45 Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996, 14:397-440.
46. 46 Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991, 34:1125-1132.
47. 47 Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN: Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992, 31:801-809.
48. 48 Romas E, Martin TJ: Cytokines in the pathogenesis of osteoporosis. Osteoporos Int 1997, 7:S47-S53.
49. 49 Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809.
50. 50 Joosten LAB, Helsen MMA, Saxne T, van de Loo FAJ, Heinegard D, van den Berg WB: IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999, 163:5049-5055.
51. 51 Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS, Jr., Haskill JS, Schwab JH: Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996, 93:402-406.
52. 52 Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al.: Treatment of rheumatoid arthritis with recombinant human interluekin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
53. 53 Finck B, Martin R, Fleischmann R, Moreland L, Schiff M, Bathon J: A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial) [abstract]. Arthritis Rheum 1999, 42:S117.
54. 54 Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie MT: Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265:144-150.
55. 55 Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269.
56. 56 Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
57. 57 Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
58. 58 Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P: Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
59. 59 Aarvak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162:1246-1251.
60. 60 Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
61. 61 Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, Miyazaki S, Kohashi O: A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol 1999, 162:2754-2760.
62. 62 McInnes IB, Leung BP, Sturrock RD, Field M, Liew F: Interleukin-15 mediates T cell-dependent regulation of tumour necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997, 3:189-195.
63. 63 McInnes IB, Liew FY: Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998, 19:75-79.
64. 64 Horwood NJ, Udagawa N, Elliot J, Grail D, Okamura H, Kurimoto M, Dunn A, Martin T, Gillespie M: Interleukin 18 inhibits osteoclast formation via T cell production of granulcyte macrophage colony-stimulating factor. J Clin Invest 1998, 101:595-603.
65. 65 Francis MD, Hovancik K, Boyce RW: NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tiss Reac 1989, 11:239-252.
66. 66 Pysklywec MW, Moran EL, Bogoch ER: Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. J Orthop Res 1997, 15:858-861.
67. 67 Eggelmeijer F, Papapoulos S, van Paassen HC, Dijkmans BAC, Valkema R, Westedt ML, Landman J-O, Pauwels E, Breedveld FC: Increased bone mass with pamidronate treatment in rheumatoid arthritis. C Arthritis Rheum 1996, 39:396-402.
68. 68 Kroger H, Arnala I, Alhava EM: Effect of calcitonin on bone histomorphometry and bone metabolism in rheumatoid arthritis. Calcif Tissue Int 1992, 50:11-13.
69. 69 Sileghem A, Geusens P, Dequeker J: Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 1992, 51:761-764.